Atypical MDR

A. Yokomizo, K. Taniguchi, S. Hasegawa, T. Abe, T. Kubo, Y. Makino, M. Wada, K. Kohno, M. Kuwano

Research output: Contribution to journalReview articlepeer-review


Multiple drug resistance (MDR) is a major clinical obstacle in cancer chemotherapy. Acquirement of MDR phenotype in cancer cells is often associated with enhanced expression of human MDR-1 gene: MDR-1 gene codes membranous P-glycoprotein which catalyses energy-dependent outward transport of anticancer agents. By contrast, MDR cancer cell lines without overexpression of P-glycoprotein are called as atypical MDR (at MDR) cells. The acquirement of at MDR has been shown to be partly associated with altered DNA topoisomerase II. Furthermore, a new ATP binding cassette (ABC) family, MRP gene has just recently shown to involve in acquirement of at-MDR in cancer cell lines, which do not express both altered topoisomerase II and P-glycoprotein.

Original languageEnglish
Pages (from-to)1123-1129
Number of pages7
JournalJapanese Journal of Cancer and Chemotherapy
Issue number8
Publication statusPublished - 1994
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Atypical MDR'. Together they form a unique fingerprint.

Cite this